Narrow Band Ultraviolet B Phototherapy Versus Oral Cyclosporine in the Treatment of Chronic Urticaria
Photodermatology, Photoimmunology & Photomedicine · 2025
DOI: 10.1111/phpp.70050 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift Photodermatology, Photoimmunology & Photomedicine, 2025. Verfasst von Nagaraja Roshini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Chronic Urticaria, Cyclosporine, Ultraviolet Therapy. Die Arbeit nennt 24 Literaturangaben. Gefördert von: IADVL Postgraduate Thesis Grant 2022.
Abstract (Originalsprache)
Background
Cyclosporine is currently recommended as a third‐line therapy for chronic spontaneous urticaria (CSU), while narrowband ultraviolet B (NB‐UVB) phototherapy has shown promise.
Objective
To compare the efficacy and safety of NB‐UVB phototherapy versus cyclosporine in antihistamine‐refractory CSU.
Methods
This randomized, prospective, non‐inferiority study recruited 50 patients with antihistamine‐refractory CSU. Participants received either NB‐UVB (thrice weekly) or cyclosporine (3 mg/kg/day) for 90 days alongside maximum‐regulated doses of antihistamines, with a post‐treatment follow‐up of 90 days. The primary outcome was the Urticaria Activity Score over 7 days (UAS7), with secondary outcomes including Urticaria Control Test (UCT), Chronic Urticaria Quality of Life (CU‐QoL), and biomarkers such as IL‐6 and IL‐31.
Results
Both treatments significantly reduced UAS7 by Day 15. NB‐UVB provided sustained symptom control post‐treatment, while cyclosporine achieved rapid relief but led to rebound flares upon discontinuation. The non‐inferiority test showed that NB‐UVB was not significantly worse than cyclosporine for UAS7 reduction. Both therapies reduced serum IgE, with IL‐6 and IL‐31 significantly decreasing in the cyclosporine group.
Limitations
Single‐center design, short follow‐up duration.
Conclusions
NB‐UVB phototherapy is an effective and well‐tolerated alternative to cyclosporine for antihistamine‐refractory CSU, offering sustained disease suppression post‐treatment. Further research is needed to explore long‐term outcomes and broader applicability. Trial Registration Clinical Trials Registry of India: CTRI/2022/11/047799
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- National Institute of Nursing Education, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Nagaraja Roshini, Hitaishi Mehta, Anuradha Bishnoi, Davinder Parsad
Förderung
- IADVL Postgraduate Thesis Grant 2022
Zitieren
APA
Roshini, N., Mehta, H., Bishnoi, A., Kumar, V., Kumar, A., Parsad, D., & Kumaran, M. S. (2025). Narrow Band Ultraviolet B Phototherapy Versus Oral Cyclosporine in the Treatment of Chronic Urticaria. Photodermatology, Photoimmunology & Photomedicine. https://doi.org/10.1111/phpp.70050
Vancouver
Roshini N, Mehta H, Bishnoi A, Kumar V, Kumar A, Parsad D, et al. Narrow Band Ultraviolet B Phototherapy Versus Oral Cyclosporine in the Treatment of Chronic Urticaria. Photodermatology, Photoimmunology & Photomedicine. 2025. doi:10.1111/phpp.70050
BibTeX
@article{Roshini2025,
author = {Roshini, Nagaraja and Mehta, Hitaishi and Bishnoi, Anuradha and Kumar, Vinod and Kumar, Ashok and Parsad, Davinder and Kumaran, Muthu Sendhil},
title = {Narrow Band Ultraviolet B Phototherapy Versus Oral Cyclosporine in the Treatment of Chronic Urticaria},
journal = {Photodermatology, Photoimmunology & Photomedicine},
year = {2025},
doi = {10.1111/phpp.70050}
}
EUVIMED